Impressively, the CDDO-Me treatment decreased tumor size across all cancer cell lines (decrease compared to vehicle: WT = 73%, KEAP1 KO = 91%, NRF2 KO = 77%), maintaining volumes less than 300 mm3 10 days post-treatment initiation. The gene discussed is NFE2L2; the disease is neoplasm.